Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Pharmarise HoldingsTSE:2796 46 EBIT per Share is 円82.95 as of May. 2026. GuruFocus rates TSE:2796 with a GF Score™ of 46/100 and a GF Value™ of 円581.10 (Modestly Undervalued). The stock has 10 warning signs investors should review. Among 524 Healthcare Providers & Services companies, Pharmarise Holdings ranks worse than 85.69% on this metric.
Pharmarise Holdings's EBIT per Share for the
six
months ended in May. 2026 was 円41.51.
Its EBIT per Share for the trailing twelve months (TTM) ended in May. 2026 was 円82.95.
During the past 12 months, the average EBIT per Share Growth Rate of Pharmarise Holdings was 218.50% per year.
During the past 3 years, the average EBIT per Share Growth Rate was -18.60% per year.
During the past 5 years, the average EBIT per Share Growth Rate was -21.50% per year.
During the past 10 years, the average EBIT per Share Growth Rate was -1.70% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Pharmarise Holdings's EBIT per Share or its related term are showing as below:
TSE:2796'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -45.8 Med: -5 Max: 45.4
Current: -18.6
During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Pharmarise Holdings was 45.40% per year. The lowest was -45.80% per year. And the median was -5.00% per year.
TSE:2796's 3-Year EBIT Growth Rate is ranked worse than 85.69% of 524
companies
in the Healthcare Providers & Services industry
Industry Median: 11.75
vs TSE:2796: -18.60
Pharmarise Holdings (TSE:2796) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Pharmarise Holdings EBIT per Share Related Terms
Pharmarise Holdings EBIT per Share Historical Data
* Premium members only.
The historical data trend for Pharmarise Holdings's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in May. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was 円82.95
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pharmarise Holdings (TSE:2796) has a EBIT per Share of 円82.95 as of May. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Pharmarise Holdings and its competitors. According to the industry distribution chart, Pharmarise Holdings ranks #449 out of 524 companies in the Healthcare Providers & Services industry, placing it in the top 85.7%.
Is Pharmarise Holdings' EBIT per Share too high?
Pharmarise Holdings' current EBIT per Share is 円82.95. Based on the distribution chart, Pharmarise Holdings ranks #449 out of 524 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Pharmarise Holdings has a GF Score™ of 46/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Pharmarise Holdings' EBIT per Share compare to competitors?
According to the Healthcare Providers & Services industry distribution chart, Pharmarise Holdings ranks #449 out of 524 companies for EBIT per Share. This places Pharmarise Holdings in the lower half of its industry. The industry median EBIT per Share is 11.75. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Healthcare Providers & Services company?
The median EBIT per Share among Healthcare Providers & Services companies is 11.75, based on 524 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Pharmarise Holdings and its competitors. For the Healthcare Providers & Services industry, the median EBIT per Share is 11.75 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pharmarise Holdings's current EBIT per Share is 円82.95. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharmarise Holdings stock overvalued right now?
Based on GuruFocus' analysis, Pharmarise Holdings (TSE:2796) is currently considered Modestly Undervalued. The stock's GF Value™ is 円581.10, compared to a current price of 円505.00 — trading 13.1% below its estimated fair value. The current EBIT per Share is 円82.95. Pharmarise Holdings' overall GF Score™ is 46/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Pharmarise Holdings (TSE:2796), the current EBIT per Share is 円82.95 as of May. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pharmarise Holdings (TSE:2796) Overvalued in 2026?
Based on GuruFocus' analysis, Pharmarise Holdings stock appears to be undervalued.
The current stock price of 円505.00 is trading 13.1% below its estimated GF Value™ of 円581.10.
GuruFocus considers Pharmarise Holdings to be Modestly Undervalued.
Key valuation signals for TSE:2796:
EBIT per Share: 円82.95
GF Value™: 円581.10 vs. price of 円505.00 (13.1% below fair value)
No single metric tells the full story. See the TSE:2796 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pharmarise Holdings Corp is engaged in the operation of dispensing pharmacies, which prescribe medicines to general patients based on the prescriptions issued by medical institutions. It is also engaged in the storage and management of medical examination records of patients on behalf of the medical institution.
46GF Score
Get the complete analysis for TSE:2796
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:2796 has been successfully added to your 
